Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents

ClinicalTrials.gov ID: NCT05347771

Public ClinicalTrials.gov record NCT05347771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents (PANDA) (CAUSE-01)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.

Study identification

NCT ID
NCT05347771
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
240 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
6 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 4, 2022 (Actual)
Primary completion
Dec 31, 2026 (Estimated)
Completion
Mar 15, 2027 (Estimated)
Last update posted
Jan 20, 2026

2022 – 2027

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Children's Hospital Colorado: Allergy Program Aurora Colorado 80045 —
Children's National Medical Center: Children's Research Institute Washington D.C. District of Columbia 20010 —
Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology Chicago Illinois 60611 —
Boston Children's Hospital: Department of Immunology Boston Massachusetts 02215 —
Washington University at St. Louis St Louis Missouri 63110 —
Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute New York New York 10029 —
Columbia University Medical Center: Division of Pediatric Pulmonology New York New York 10032 —
Cincinnati Children's Hospital Medical Center: Asthma Center Cincinnati Ohio 45229 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05347771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 20, 2026 · Synced Oct 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05347771 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →